Trials / Completed
CompletedNCT00338026
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Thallion Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ECO-4601 | Continuous IV infusion for 14 days with 7 days recovery (21 day cycle) |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-06-20
- Last updated
- 2008-07-15
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00338026. Inclusion in this directory is not an endorsement.